Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 21 min ago
Peer-reviewedCC BY 4.0Cancers

Navigating T-Cell-Directed Therapies in Transformed Follicular Lymphoma

  • Viktoriya Zelikson1
  • Reem Karmali2
  1. 1Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
  2. 2Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Open at sourceDOICite

Abstract

T-cell-engaging therapies have revolutionized care for relapsed or refractory large B-cell lymphoma. Transformed follicular lymphoma (tFL) has had limited representation in CAR-T or bispecific antibody trials. Thus, outcomes in this subgroup are not well-described. Furthermore, trials that include aggressive disease transformed from indolent lymphomas often report collective outcomes rather than results for individual histologic subsets despite biologic heterogeneity; this limits interpretability of results. Despite these limitations, there are consistent signals that tFL responds well to T-cell-engaging therapies. tFL has a unique tumor microenvironment, but it is not clear if or how this contributes to the favorable outcomes. More robust data are available for CAR-T compared to bispecifics in this population and differences in responsiveness between the two therapies are difficult to ascertain. More research is needed to better understand biologic interaction of tFL with T-cell-engaging therapies and response to therapy to inform future clinical trials.

Related

  1. FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
    Rachel Ershler, Xueping Zhou, Keng Hee Peh +12
    Clinical cancer research : an official journal of the American Association for Cancer ResearchPeer-reviewedLicence not statedFull textGeneral medicinePMC
  2. Ocular Follicular Lymphoma with Marginal Zone Differentiation: A Diagnostic Pitfall Mimicking MALT Lymphoma
    Takashi Miyachi, Akihiro Kitadate, Wataru Kuroki +3
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  3. Status Epilepticus as the Initial Manifestation of Follicular Lymphoma with Leptomeningeal Dissemination
    Momoyo Ibukuro, Kenichi Sakuta, Motohiro Okumura +6
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textNeurologyJ-STAGE
  4. Follicular Lymphoma Involving the Supraglottic Larynx in a Patient with Recurrent Cutaneous B-cell Lymphoproliferative Lesions: A Case Report
    Ryohei Asai, Hiroumi Matsuzaki, Shimon Otake +2
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  5. Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies☆
    Aleena Banerji, Jonathan A. Bernstein, Laurence Bouillet +11
    The World Allergy Organization journalPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{zelikson2026navigating,
  title = {{Navigating T-Cell-Directed Therapies in Transformed Follicular Lymphoma}},
  author = {Viktoriya Zelikson and Reem Karmali},
  journal = {Cancers},
  year = {2026},
  month = oct,
  doi = {10.3390/cancers18203391},
  url = {https://www.mdpi.com/2072-6694/18/20/3391},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Navigating T-Cell-Directed Therapies in Transformed Follicular Lymphoma
AU  - Viktoriya Zelikson
AU  - Reem Karmali
PY  - 2026
DA  - 2026/10/20
JO  - Cancers
DO  - 10.3390/cancers18203391
UR  - https://www.mdpi.com/2072-6694/18/20/3391
AB  - T-cell-engaging therapies have revolutionized care for relapsed or refractory large B-cell lymphoma. Transformed follicular lymphoma (tFL) has had limited representation in CAR-T or bispecific antibody trials. Thus, outcomes in this subgroup are not well-described. Furthermore, trials that include aggressive disease transformed from indolent lymphomas often report collective outcomes rather than results for individual histologic subsets despite biologic heterogeneity; this limits interpretability of results. Despite these limitations, there are consistent signals that tFL responds well to T-cell-engaging therapies. tFL has a unique tumor microenvironment, but it is not clear if or how this contributes to the favorable outcomes. More robust data are available for CAR-T compared to bispecifics in this population and differences in responsiveness between the two therapies are difficult to ascertain. More research is needed to better understand biologic interaction of tFL with T-cell-engaging therapies and response to therapy to inform future clinical trials.
SN  - 2072-6694
ER  -